Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

Promega's Cookie Policy

We use cookies and similar technologies to make our website work, run analytics, improve our website, and show you personalized content and advertising. Some of these cookies are essential for our website to work. For others, we won’t set them unless you accept them. To find out more about cookies and how to manage cookies, read our Cookie Policy.

Back 2 the Bench is Back! Save 25% On Reagents & 10% On Instruments the entire month of June. Register Now ›

Small Molecule Drug Discovery

The process of small molecule drug discovery can be complex and challenging. A typical workflow begins with hit identification and assay development, and carries through to preclinical candidate selection. High-throughput screening of drug candidates plays in essential role in the drug discovery process.

Promega offers a comprehensive selection of tools to accelerate drug discovery, based on an innovative, sensitive bioluminescence platform.

Services

support for cros

Support for CROs

Discover how Promega can help your contract research organization (CRO) develop better solutions for your clients.

Learn More
elite acccess services and materials

Elite Access

Partner with us to access our latest technologies and materials for drug discovery research and development.

Learn More

Drug Discovery Conferences and Tradeshows

Promega scientists will be attending and speaking at key drug discovery conferences and tradeshows throughout the year. Join us to learn more about innovative solutions to accelerate your research.

 

Event Name 2021 Dates Location Presentations
SLAS 2021 Digital International Conference and Exhibition January 25-27 Virtual (PST) Target Engagement Tutorial
PARP & DDR Inhibitors Summit January 26-28 Virtual (EST)  
North American Protein Degradation Congress February 16-17, 23-24 Virtual (EST) Flagship Presentation
RAS Targeted Drug Discovery February 23-25 Virtual (GMT) Featured Presentation
Targeted Protein Degradation (TPD) Europe March 16-18 Virtual (GMT) Presentation
Undruggable Leaders Forum Europe April 13-14 Virtual (BST) Plenary Presentation
DDC (Drug Discovery Chemistry) May 18-20 Virtual (PST) Presentation
Ligase Targeting Drug Development May 25-27 Virtual (EDT) Featured Presentation
Induced Proximity-Based Drug Discovery Summit June 29-July1 Virtual (EDT) Workshop
Undruggable Leaders Forum US September 15-16 Virtual (EDT)  
RAS Targeted Drug Development September 21-23 Virtual (EDT)  
European Protein Degradation Congress September 22-23 Basel, Switzerland  
Discovery on Target September 27-30 Boston, MA and Virtual (EDT)  
4th Targeted Protein Degradation (TPD) October 26-29 Virtual (EDT)  
Inflammasome Therapeutics Summit November 4-6 TBD  Presentation

Interested in more information about small-molecule drug discovery?
We can customize a presentation to answer your questions.

Request a Seminar

About Small Molecule Drug Discovery

The pathway from identification of a novel drug candidate to preclinical trials can be complex. From screening compound libraries to measuring the interaction of a compound with its protein targets to examining the effects on cell health, the process of drug discovery relies on rapid, sensitive and high-throughput assays.

Technologies developed by Promega can help streamline the drug discovery process. NanoBRET™ target engagement assays quantitatively measure target occupancy and compound affinity in live cells. A comprehensive collection of CRISPR-edited cell lines and clones with popular targets fused to a small bioluminescent tag, supports these live-cell assays. In addition, these engineered cells are ideal for studying the effects of degrader compounds, such as PROTACs, IMiDs and molecular glues, in real time. Bioluminescence technology also forms the basis for assays to examine signaling pathways in kinase biology and to study oncogenesis, such as the RAS signaling pathway.

Our small molecule drug discovery products and technologies are supported by a range of services, including our partnerships with CROS and early access to the latest research products and technologies through our Elite Access program.